Biotech Values

[DewDiligence]

Based on MNTA’s limited expedited discovery, MNTA told the Court yesterday that Amphastar does infringe MNTA’s ‘466 patent, which covers the 1,6 anhydro structural component of Lovenox that the FDA said is a requirement for showing sameness to branded Lovenox.

Based on the same expedited discovery, MNTA also told the Court that Amphastar does not infringe on MNTA’s ‘886 patent, so you no longer need to worry about the claims in that patent.

Source: MNTA’s webcast at today’s BioCentury conference (http://phx.corporate-ir.net/phoenix.zhtml?c=136783&p=conferenceAgenda&id=4170520&day=1 )